上海交通大学学报（医学版）

›› 2010, Vol. 30 ›› Issue (12): 1569-.doi: 10.3969/j.issn.1674-8115.2010.12.028

• 综述 • 上一篇    下一篇

他汀类药物在慢性阻塞性肺疾病治疗中的研究进展

周 健, 凌美蓉, 邓星奇   

  1. 上海瑞金医院集团闵行中心医院急诊科, 上海 201100
  • 出版日期:2010-12-25 发布日期:2010-12-31
  • 作者简介:周 健（1976—）, 男, 住院医师, 学士；电子信箱: zj021976@163.com。

Research progress of role of statins in treatment of chronic obstractive pulmonary disease

ZHOU Jian, LING Mei-rong, DENG Xing-qi   

  1. Department of Emergency, Minhang Central Hospital, Shanghai Ruijin Hospital Group, Shanghai 201100, China
  • Online:2010-12-25 Published:2010-12-31

PDF (PC)

1679

摘要：

慢性阻塞性肺疾病（COPD）是一种具有气流受限特征的可以预防和治疗的疾病。气流受限不完全可逆，呈进行性发展，与肺部对有害气体或颗粒的异常炎症反应有关。他汀类药物是3-甲基戊二酰辅酶A（HMG-CoA）还原酶抑制剂，是最为经典和有效的降脂药物，广泛应用于心血管疾病的治疗。近年来研究发现，他汀类药物通过抗金属蛋白酶、抗氧化、抗炎症介质及细胞因子、抑制黏附分子表达、降低C反应蛋白等环节起到抗炎作用，缓解了COPD患者的肺功能，降低了发病率和病死率。

关键词: 他汀类药物, 慢性阻塞性肺疾病, 治疗

Abstract:

Chronic obstructive pulmonary disease (COPD) is characterized by progressive and minimally reversible airflow limitation with systemic inflammation, which can be prevented and treated. Statins reduce cholesterol levels by inhibiting 3-hydroxy-3-methlglutaryl coenzyme A(HMG-CoA) reductase, and have an established role in the treatment of cardiovascular diseases. Recent studies have revealed that statins have profound anti-inflammatory effects by reducing induction of matrix metalloproteinase, expression of cytokines and cell adhesion molecules, antioxidant state and C-reactive protein, which decreases lung function deterioration, morbidity and mortality in COPD.

Key words: statins, chronic obstractive pulmonary disease, therapy